391 related articles for article (PubMed ID: 21852274)
21. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
23. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
[TBL] [Abstract][Full Text] [Related]
26. Treatment of antibody-mediated rejection of kidney grafts with bortezomib and/or rituximab compared to standard regimen: experience of Slovene National Center.
Oblak T; Lindič J; Gubenšek J; Kveder R; Aleš Rigler A; Škoberne A; Večerić Haler Ž; Borštnar Š; Avguštin N; Ponikvar R; Mlinšek G; Ferluga D; Kojc N; Godnov U; Kovač D
Clin Nephrol; 2017 Supplement 1; 88(13):91-96. PubMed ID: 28664838
[TBL] [Abstract][Full Text] [Related]
27. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
[TBL] [Abstract][Full Text] [Related]
28. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
Fehr T; Gaspert A
Transpl Int; 2012 Jun; 25(6):623-32. PubMed ID: 22394269
[TBL] [Abstract][Full Text] [Related]
29. A summary of bortezomib use in transplantation across 29 centers.
Everly MJ
Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
[TBL] [Abstract][Full Text] [Related]
30. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
[TBL] [Abstract][Full Text] [Related]
32. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
33. Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience.
Cicora F; Paz M; Mos F; Roberti J
Transpl Immunol; 2013 Dec; 29(1-4):7-10. PubMed ID: 23994721
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
36. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibition reduces donor-specific antibody levels.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitor therapy for antibody-mediated rejection.
Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]